133 related articles for article (PubMed ID: 24951903)
1. [Cost analysis of the use of botulinum toxin type A in Spain].
de Andrés-Nogales F; Morell A; Aracil J; Torres C; Oyagüez I; Casado MA
Farm Hosp; 2014 May; 38(3):193-201. PubMed ID: 24951903
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
3. AbobotulinumtoxinA (Dysport
Field M; Splevins A; Picaut P; van der Schans M; Langenberg J; Noort D; Snyder D; Foster K
Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551641
[TBL] [Abstract][Full Text] [Related]
4. Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®.
Frevert J
Drugs R D; 2010; 10(2):67-73. PubMed ID: 20698714
[TBL] [Abstract][Full Text] [Related]
5. [Use of botulinum neurotoxin therapy].
Mukai Y; Kaji R
Brain Nerve; 2011 Jul; 63(7):775-84. PubMed ID: 21747148
[TBL] [Abstract][Full Text] [Related]
6. To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study.
Tedroff K; Befrits G; Tedroff CJ; Gantelius S
Eur J Paediatr Neurol; 2018 May; 22(3):412-418. PubMed ID: 29452742
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia.
Danchenko N; Johnston KM; Whalen J
J Med Econ; 2022; 25(1):919-929. PubMed ID: 35730362
[TBL] [Abstract][Full Text] [Related]
8. Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap.
Ertzgaard P; Anhammer M; Forsmark A
Acta Neurol Scand; 2017 Mar; 135(3):366-372. PubMed ID: 27220381
[TBL] [Abstract][Full Text] [Related]
9. Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits.
Kazerooni R; Howard I; Li X; Verduzco-Gutierrez M
Arch Phys Med Rehabil; 2022 Jun; 103(6):1205-1209. PubMed ID: 34852255
[TBL] [Abstract][Full Text] [Related]
10. Safety of botulinum toxin type A in children younger than 2 years.
Pascual-Pascual SI; Pascual-Castroviejo I
Eur J Paediatr Neurol; 2009 Nov; 13(6):511-5. PubMed ID: 19036619
[TBL] [Abstract][Full Text] [Related]
11. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
12. Evidence on botulinum toxin in selected disorders.
Zakin E; Simpson D
Toxicon; 2018 Jun; 147():134-140. PubMed ID: 29408357
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
14. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
Scaglione F
Toxins (Basel); 2016 Mar; 8(3):. PubMed ID: 26959061
[TBL] [Abstract][Full Text] [Related]
15. Dysport (botulinum toxin type A) in routine therapeutic usage: a telephone needs assessment survey of European physicians to evaluate current awareness and adherence to product labeling changes.
Hubble J; Schwab J; Hubert C; Abbott CC
Clin Neuropharmacol; 2013; 36(4):122-7. PubMed ID: 23783005
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin A for treating spasticity in adults: costly for French hospitals?
Schnitzler A; Ruet A; Baron S; Buzzi JC; Genet F
Ann Phys Rehabil Med; 2015 Oct; 58(5):265-8. PubMed ID: 26234276
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the cost per patient per injection of botulinum toxin A in upper limb spasticity: comparison of two preparations in 19 countries.
Roze S; Kurth H; Hunt B; Valentine W; Marty R
Med Devices (Auckl); 2012; 5():97-101. PubMed ID: 23204875
[TBL] [Abstract][Full Text] [Related]
18. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
Wissel J; Entner T
Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
[TBL] [Abstract][Full Text] [Related]
19. The broadening application of chemodenervation in X-linked dystonia-parkinsonism (Part II): an open-label experience with botulinum toxin-A (Dysport®) injections for oromandibular, lingual, and truncal-axial dystonias.
Rosales RL; Ng AR; Santos MM; Fernandez HH
Int J Neurosci; 2011; 121 Suppl 1():44-56. PubMed ID: 21348790
[TBL] [Abstract][Full Text] [Related]
20. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
